Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals

PURPOSE: The 21-gene recurrence score (RS) is a genomic test developed as a prognostic and predictive tool to improve the treatment decision making in cases of estrogen receptor-positive and human epidermal growth factor receptor 2-negative early-stage breast cancer. This study examined the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez del Prado, Purificación, Alvarez-López, Isabel, Domínguez-Fernández, Severina, Plazaola, Arrate, Ibarrondo, Oliver, Galve-Calvo, Elena, Ancizar-Lizarraga, Nerea, Gutierrez-Toribio, María, Lahuerta-Martínez, Ainhara, Mar, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863711/
https://www.ncbi.nlm.nih.gov/pubmed/29593426
http://dx.doi.org/10.2147/CEOR.S146095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863711/
https://www.ncbi.nlm.nih.gov/pubmed/29593426
http://dx.doi.org/10.2147/CEOR.S146095

Ejemplares similares